Roth Capital analyst, Scott Henry, reiterated his Buy rating on shares of Catalyst Pharmaceutical Partners (NASDAQ: CPRX) after meeting with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE